Company

Axonics, Inc.

Headquarters: Irvine, CA, United States

Employees: 517

CEO: Mr. Raymond W. Cohen

NASDAQ: AXNX -0.20%

Market Cap

$2.92 Billion

USD as of Jan. 1, 2024

Market Cap History

Axonics, Inc. market capitalization over time

Evolution of Axonics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Axonics, Inc.

Detailed Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Axonics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: AXNX wb_incandescent

Stock: FSX: 0I3 wb_incandescent

Details

Headquarters:

26 Technology Drive

Irvine, CA 92618

United States

Phone: 949 396 6322

Fax: 949 396 6321